Pay in 4 interest-free payments of $5.04 Learn more
Ships within 48 hours · Estimated delivery Sep 24 - Sep 29
Mark Eisenberg , James McGill Professor, Department of Medicine, McGill University , Senior Investigator, Lady Davis Institute, Jewish General Hospital mark.eisenberg [at] mcgill.ca (English, French)
The GLP-1 obesity home delivery injectables market in the UK is expanding at a CAGR of 13.5%, supported by rising obesity awareness and increasing use of pharmacological weight-management therapies
The frozen aisle is evolvingdriven in part by how eating habits are changing, including the impact of GLP1 medications
The medications ability to regulate appetite and reduce inflammation addresses core IBS symptoms, while its impact on gastrointestinal symptoms shows promise in managing bloating and irregular bowel habits
US$ 22.19
US$ 29.70
US$ 26.52
US$ 24.39
